rheumatoid arthritis News
-
USPTO Awards Another Patent; New Data Demonstrating 14-3-3? as a Biomarker for Monitoring Therapy Response
USPTO Awards Patent for Citrullinated 14-3-3: Expanding Augurex’s Portfolio in the Diagnosis of Rheumatoid Arthritis (RA) On November 20th, 2018 the US Patent and Trademark Office (USPTO) awarded patent number 10,132,806 entitled “Antigens Derived From Citrullinated 14-3-3 And Uses Thereof In The Diagnosis of Rheumatoid Arthritis.” Citrullinated 14-3-3η auto-antibodies are ...
-
Setpoint Medical announces oral presentation of results from U.S. Pilot Study in Rheumatoid Arthritis Patients at American College of Rheumatology (ACR) Annual Meeting 2019
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that results from its U.S. pilot Investigational Device Exemption (IDE) study in rheumatoid arthritis (RA) have been accepted for oral presentation at the American College of Rheumatology (ACR) Annual Meeting, being held November 8-13, 2019 in Atlanta, GA. The ...
-
LISCure Biosciences received clinical approval for two microbiome programs targeting autoimmune disease and NASH
LISCure Biosciences ("LISCure") announced that it has received approval for a global phase 1 clinical trial for two programs, LB-P6 and LB-P8, targeting autoimmune disease and non-alcoholic steatohepatitis (NASH), respectively. This achievement is significant in that it will be the first global clinical trial among the microbiome treatments for rheumatoid arthritis and NASH indications. The most ...
-
SetPoint Medical Appoints Amy Derosier as Vice President of Clinical Affairs
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapies for chronic autoimmune diseases, today announced the appointment of Amy Derosier as Vice President of Clinical Affairs. “Amy’s extensive experience in successfully designing and executing clinical trials for novel medical devices complements that of our CMO, Dr. David Chernoff, who has extensive ...
-
Runway Growth Capital Announces a Senior Secured Term Loan of $35 Million to SetPoint Medical
Runway Growth Capital LLC (“Runway”), a leading provider of growth loans to both venture and non-venture backed companies seeking an alternative to raising equity, today announced the close of a senior secured term loan of $35 million to SetPoint Medical (“SetPoint”), a Valencia, California based, privately-held clinical-stage bioelectronic medicine company developing ...
-
More Precise RA Patient Care; New data on the 14-3-3? blood test to help optimize treat-to-target strategies
At the annual European congress of rheumatology meeting, The European League Against Rheumatism (EULAR), taking place in Amsterdam on June 13th-16th, leading investigators from United States, Israel, and Egypt will present new data on the 14-3-3η blood test. Several of these studies grow the body of evidence of 14-3-3η’s key role as an early diagnostic test that assists with ...
-
GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner, GSK plc (LSE/NYSE: GSK), provided an update on the ContRAst phase III program for otilimab as a potential treatment of moderate to severe rheumatoid arthritis (RA). The ContRAst phase IIl program enrolled a broad range of difficult-to-treat patients who had an inadequate response to or could not tolerate available ...
By MorphoSys AG
-
SetPoint Medical Receives FDA Breakthrough Device Designation for its Novel Bioelectronic Platform
SetPoint Medical, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel bioelectronic device for patients with rheumatoid arthritis (RA) who have incomplete response to, or are intolerant to multiple biologic drugs. The Company is developing its platform for the treatment of chronic, ...
-
SetPoint Medical Receives IDE Approval for U.S. Pivotal Trial to Study its Bioelectronic Platform in Rheumatoid Arthritis Patients
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to study its proprietary bioelectronic platform in patients with rheumatoid arthritis (RA). The multicenter, double-blind, randomized, sham ...
-
DT MedTech Announces 510(k) FDA Clearance for Hintermann Series H2 Total Ankle Replacement System
DT MedTech, LLC (DTM) today announced that the Hintermann Series H2 Total Ankle Replacement System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The Hintermann Series H2 is a semi-constrained, total ankle replacement prosthesis developed by Prof. Beat Hintermann, a world-renowned foot and ankle surgeon based in Liestal, Switzerland. The Hintermann Series H2 ...
-
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed resultsfrom the Adaptive COVID-19 Treatment Trial (ACTT-2) published in the New England Journal of Medicine showed that baricitinib in combination with remdesivir reduces recovery time, improves clinical status and demonstrates a trend towards a decrease in mortality in hospitalised COVID-19 patients with pneumonia. Those who took both drugs had a median time to recovery of seven ...
By Benevolent
-
SetPoint Medical to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum 2019
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that Murthy Simhambhatla, Ph.D., President and Chief Executive Officer, is scheduled to present at the 13th annual Canaccord Genuity Medical Technologies & Diagnostics Forum, being held November 21, 2019 in New York, New York. Event: Canaccord Genuity ...
-
Galapagos announces changes to Executive Committee
Dr. Walid Abi-Saab has decided to retire from the company as Chief Medical Officer and member of the Executive Committee, effective 31 December 2022. He will stay with Galapagos until 31 May 2023 to ensure a smooth transition. The company also announces the retirement of André Hoekema who joined Galapagos in 2005 as Chief Business Officer and member of the Executive Committee. Dr. Paul ...
By Galapagos NV
-
What Are D-Glucosamines?
Glucosamine is a natural component of cartilage and is widely used as an over-the-counter nutritional supplement to reduce the pain and cartilage loss of osteoarthritis. Glucosamine is usually taken in combination with chondroitin, which is a glycosaminoglycan that also exists in cartilage.Glucosamine is an amino sugar and an important molecule in the biochemical pathway of glycosylated protein ...
-
Call for applications: the Amgen award for science teaching excellence
Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE). This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student learning in communities where Amgen ...
-
Augurex and Quidel at ACR
Augurex and Quidel are pleased to announce the launch of the JOINTstat® 14-3-3η RUO (research use only) ELISA. This new distribution arrangement will get 14-3-3η testing into the hands of more investigators worldwide, including key opinion leaders and pharmaceutical companies, to advance and grow the body of data for this novel joint damage biomarker in autoimmune diseases. There is ...
-
KiOmed Pharma appoints seasoned industry executives and expands its board of directors
KiOmed Pharma announces the appointment of two seasoned biotech executives: Dr Pierre Rigaux, MD, PhD is joining its Board of Directors, and Dr Mathias Schifflers, MD is appointed Chief Medical Officer and joins its executive management team “We are absolutely delighted to announce the appointment of Dr Pierre Rigaux to our Board of Directors. Pierre is an extremely well-regarded executive ...
-
Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders. “JAK inhibitors are an important treatment option ...
By Galapagos NV
-
SetPoint Medical to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum 2019
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that Murthy Simhambhatla, Ph.D., President and Chief Executive Officer, is scheduled to present at the 13th annual Canaccord Genuity Medical Technologies & Diagnostics Forum, being held November 21, 2019 in New York, New York. Event: Canaccord Genuity ...
-
Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 10, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the launch of its oncology and autoimmune discovery and development platform with an initial focus on indications including, but not limited to, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you